IL17A and myasthenia gravis: In addition, such preparations can reduce the level of AChR antibody and IFN-γ, TNF-α, IL-6, IL-17, and other immune factors levels, which is similar to the results of this study, indicating that intestinal microbiota can participate in the pathogenesis and development of MG (Chae et al., 2012).